I am accepting new patients.

In Practice Since:

1995

Honors and Awards:

1994, 1995 American College of Allergy, Asthma & Immunology

Travel Awards

1993 American Academy of Allergy, Asthma & Immunology

Travel Awards

1992 Cleveland Clinic Pediatric Resident 

Research Day Award

1991 American Society for Pediatric Research

Travel Award

1990 The Cleveland Clinic Foundation Graduate-Level

One Alumni Association Award

1985 University of Jordan Leadership Award

SCIENTIFIC COMMITTEES

1997-2000 Continuing Education Committee 

Jordan University Hospital

1997-2000 Scientific Research Committee 

School of Medicine, University of Jordan

1995-2000 Latex Committee

American College of Allergy, Asthma & Immunology

1995-1997 Latex Allergy Task Force

Cleveland Clinic Foundation

1991-1993 Scientific Publications Committee

Cleveland Clinic Foundation

Publications:

Kim K.T., Safadi G.S. Relation of latex specific IgE titer and symptoms in patients allergic to latex. Journal of Allergy & Clinical Immunology 1999; 103 (4): 671-77.

Kim, K.T., Graves, P.B., Safadi, G.S. Implementation recommendations for making health care facilities latex safe. AORN Journal 1998; 67:615-632.

Kim, K.T., Safadi, G.S., Sheikh, K. Diagnostic evaluation of Type I latex allergy. Annals of Allergy, Asthma & Immunology 1998; 80: 66-70.

Aamir R., Safadi, G.S., Cornish, K., Melton, A.L., Wagner, W.O., Battisto, J.R. Shared IgE-binding epitopes in latex. International Archives of Allergy & Immunology 1996; 111(1): 48-54.

Safadi, G.S., Corey, E.C., Taylor, J.S., Wagner, W.O., Pien, L.C., Melton, A.L. Latex hypersensitivity in emergency medical service providers. Annals of Allergy, Asthma & Immunology 1996; 77(1): 39-42.

Terezhalmy G.T., Esposito, S.J., Safadi, G.S. Immunopharmacology. Dental Clinics of North America 1996; 40(1): 685-707.

Safadi, G.S., Safadi, T.J., Terezhalmy, G.T., Taylor, J.S., Battisto, J.R., Melton, A.L. Latex hypersensitivity: its prevalence among dental professionals. Journal of the American Dental Association 1996; 127(1): 83-88.

Safadi, G.S., Corey, E.C. Danger lurks in latex. Emergency 1995; 27(10): 56-61.

Safadi, G.S. Computer Software, Pediatric cough & fever: an exercise in clinical problem solving. Clinical Pediatrics [Book Review] 1990; 30(6): 390.

Safadi, G.S., Wagner, W.O., Pien L.C. Melton A.L. Latex-induced anaphylaxis following routine medical examination. Annals of Allergy & Immunology 1996; 74(1): p 77.

Safadi G.S., Saradi T.J., Terezhalmy, G., Melton, A.L. Latex hypersensitivity: a study of prevalence in a hospital dental practice. Annals of Allergy, Asthma & Immunology 1995; 74(1): p57.

Goske, M., Safadi, G.S., Melton, A.L., Frankel, D. Latex hypersensitivity in the radiology department: an update. Pediatric Radiology 1994.

Safadi, G.S., Melton, A.L., Wagner, W.O. Banana anaphylaxis in latex hypersensitive health care workers. Journal of Allergy & Clinical Immunology 1994; 93(1), 2: p 283.

Safadi, G.S., Battisto, J.R., Chikkala, N. Recombinant human interleukin-10 (rhIL-10) affects in in vitro development of interleukin-2 activated killer cells. Pediatric Research 1993; 33(4), 2: 146A.

Safadi, G.S., Wyllie, R., Caulfield, M., Steffen, R., Vogt, D., Broughan, T. Correlation of biochemical parameters and graft rejection in pediatric and adult orthotopic liver transplant patients. North American Society for Pediatric Gastroenterology and Nutrition 1993.

Steffen, R., Safadi, G.S., Wyllie, R., Biscotti, C., Caulfield, M., Fazio, V. Intestinal pseudo-obstruction secondary to histiocytosis x in a child. Gastroenterology 1991; 100(5), 2: A167.

Mechanisms to reduce latex hypersensitivity - [PRC #5125] Approved for international funding by the Cleveland Clinic Research Protocol Committee August 1995.

Phase III, Multicenter, Clinical study to document performance of the prototype Non-ammoniated latex as a diagnostic testing material - (John Hopkins-IND #4920). [IRB 1147] Approved by the Cleveland Clinic Institutional Review Board April 1995.

Latex Hypersensitivity: I. A study of the level of awareness and prevalence of latex hypersensitivity among Emergency Medical Workers in the city of Cleveland. II. Determination of the allergenic protein(s) in latex. [RPC #4902] - Approved for internal funding by the Cleveland Clinic Research Protocol Committee November 1994.

Latex Hypersensitivity: Determination of prevalence in a population of health care workers, and determination of the allergenic protein(s) in latex - [RPC #4429] Approved for internal funding by the Cleveland Clinic Research Protocol Committee January 1994.

Establishing two animal models (mouse and guinea pig) for latex hypersensitivities: Immediate (Type I) and delayed - (Type IV). [RPC #4435] ] Approved for internal funding by the Cleveland Clinic Research Protocol Committee August 1993.

Production of antibodies to soluble components of latex in rabbits - [RPC #4232] Approved for internal funding by the Cleveland Clinic Research Protocol Committee January 1993.

Studying the effect of Interleukins 2,4 and 10 on the Development of Cytotoxic T lymphocytes and lymphokine activated killer cells in vetro - [RPC #3869] Approved for internal funding by the Cleveland Clinic Research Protocol Committee January 1992.

 - Anaphylaxis

 - Asthma Pathophysiology and Management in Adults and Children

 - Rhinitis and Sinusitis

 - Transplant Immunology

 - T Cell Subtypes (Th1 / Th2) and Their Role in Disease

 - Immune Tolerance, Mechanisms, Role in Disease Etiology

 - Interleukin -10, Cytokine Synthesis Inhibitory Factor

 - IgE and IgG: Role in Allergy and Disease

Efficacy and Safety of ?vs. its Components in the Treatment of Subjects with Seasonal Allergic Rhinitis for Schering Plough Research Institute, 2000.

A Randomized, Double-Blind, Parallel-Group Comparison of the Safety and Efficacy of Three Ounce Daily Doses of ? with Placebo and ? 10 mg Daily in Patients with Symptomatic Asthma for Bayer Corporation, 2000.

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-week Trial of ? versus Placebo in ?in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroids Therapy for Glaxo Wellcome Inc., 2000.

A Randomized, Double-Blind, Parallel-Group Trial Assessing the Efficacy and Safety of ? and Placebo in Subjects at Least 12 Years of Age with Chronic Asthma Currently Treated with Inhaled Corticosteriods for Glaxo Wellcome Inc., 2000.

Validation of a Nocturnal Rhinitis Quality of Life (NRQLQ) Questionnaire for RPR, 2000.

Efficacy and Safety of Two Formulations of ? Compared to ? and ? Sustained Release, in the Treatment of Subjects With Seasonal Allergic Rhinitis for Schering-Plough Research Institute, 2000.

A Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study of ? in Female Subjects with Alternating Diarrhea/Constipation Irritable Bowel Syndrome (IBS) for Glaxo Wellcome Inc., 2000.

A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Phase II Study to Assess the Clinical Efficacy of ? in Male Subjects with Irritable Bowel Syndrome for Glaxo Wellcome Inc., 2000.

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of ? versus ?versus Placebo in the Treatment of Subjects Twelve Years and Older with Seasonal Allergic Rhinitis for Pfizer, Inc., 2000.

A Study of the Effect of ? and ? on Nasal Stuffiness in Subjects with Seasonal Allergic Rhinitis for Schering-Plough Institute, 2000.

A 12-Month Study to Assess the Safety and Efficacy of ? in Obese Adolescents for Knoll Pharmaceutical Company, 2000.

A Comparative Efficacy Study of ? and ? in Patients with Erosive Esophagitis for AstraZeneca, 2000.

An Open -Label Study to Evaluate the Safety of ? for the Treatment of Atopic Dermatitis for Fujisawa Healthcare, Inc., 2000.

A Randomized, Double-Blind, Parallel-Group, Comparative Trial of ? versus ? in Adolescents and Adults with Moderate Persistent Asthma for Glaxo Wellcome Inc., 2000.

A Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of ? for Control of Bowel Urgency in Females with Nonconstipated Irritable Bowel Syndrome for Glaxo Wellcome Inc., 2000.

Adolescent Obesity: A 12-month study to assess the safety and efficacy of ? 10 mg and 15 mg in obese adolescents ages 12-16 years, 

Knoll, 2000.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Orlistat Plus Diet in Obese Hypertensive

Patients Inadequately Controlled with Antihypertensive Medications for Roche Laboratories, Inc., 2001.

Pediatric Spring Allergy: A double-blind, randomized, placebo-controlled, parallel group study assessing the efficacy and safety of ? BID

in pediatric subjects (6-11 years) in the treatment of seasonal allergic rhinitis, Aventis, 2001.

SAR ? Advil multi-symptom allergy sinus efficacy and safety study, Whitehall Robbins, 2001.

Asthma: A randomized, double-blind, double-dummy, placebo-controlled, parallel group, multiple dose study of the potential effects of ?

and ? on HPA-axis in adult asthma patients, Aventis, 2001.

Asthma: A randomized, double-blind, parallel-group, placebo-controlled, 12-week trial of inhaled ? 88mcg BID, 220mcg BID, 440mcg 

BID versus placebo in ? in adolescent and adult subjects with asthma who are maintained on inhaled corticosteriod therapy,

GlaxoWellcome, 2001.

Spring Allergy ? Screening protocol to identify subjects who exhibit difficulty in tolerating a high dose of ?, Schering Plough, 2001.

Spring Allergy ? Pilot study to investigate the efficacy and safety of a combination of ? versus ? versus placebo, in subjects with seasonal

allergic rhinitis, Schering Plough, 2001.

A randomized, double-blind, placebo-controlled, parallel group study of four doses of ? as an open active-control in the treatment of adults

and adolescents with allergic rhinitis induced by grass pollen, Muro Pharmaceuticals, 2001.

CLINICAL TRIALS (Continued)

Screening protocol to identify subjects who exhibit difficulty tolerating a high dose of ?, Schering Plough, 2001.

Efficacy and safety of combination ? vs. ? and placebo in the treatment of subjects with seasonal allergic rhinitis, Schering Plough, 2001.

Efficacy and safety of combination ? vs. ? and placebo in the treatment of subjects with seasonal allergic rhinitis and a history of perennial

allergic rhinitis, Schering Plough, 2001.

Randomized, double-blind ? comparison of ? vs. ? vs. placebo in subjects with COPD, GlaxoWellcome, 2001.

A double-blind ? randomized, placebo-controlled ? study to assess the safety and efficacy of ? in adolescent and adult patients

Chronic-dose comparison of the efficacy and safety of ? in mild to moderate asthmatics, Baker Norton, 2001.

An open, randomized, parallel group, multicenter trial to compare a stratified care treatment regimen based on MigraineDisability (MIDAS 

An open-label, randomized, multiple dose, parallel, multicenter study of ? in the treatment of Gastroesophageal Reflux (GER) symptoms in 

A Multi-Center, Double-Blind, Double-Dummy, Parallel-Group, 8-Week Comparison of ? Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease for Glaxo Wellcome Inc., 2001.

Cardiovascular Treatment Assessment Versus ? for Bristol-Myers Squibb Company, 2001.

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Assessing the Efficacy and Safety of ? in Pediatric Subjects (6 to 11 Years) in the Treatment of Seasonal Allergic Rhinitis for Hoechst Marion Roussel, 2001.

Pediatric Growth Study: mmA Phase III, multicenter, double-blind, placebo-controlled, non-inferiority study assessing the effects of ?MDI

50mcg/day and 200 mcg/day (ex-valve) administered once daily on growth in children (5-8 years) with mild, persistent asthma,

Aventis, 2001.

Multicenter, double-blind, randomized, parallel group study of ? vs. placebo in patients with asthma, Altana, 2001.

A 12 week prospective, randomized, double-blind, placebo-controlled, fixed-dose, parallel group study of the safety and efficacy of ? BID

and ? TID in female patients with constipation-predominant irritable bowel syndrome with a 6 month open label extension, Forest

Labs, 2001.

A double-blind, placebo-controlled study of the effect of ?in subjects with perennial allergic rhinitis, Schering Plough Research Institute, 

2002.

A repeat-dose, placebo and active controlled, multicenter efficacy and safety study of a tablet containing ?in subjects with symptoms of cold or flu, Whitehall-Robins Healthcare, 2002. 

A randomized, double-blind, parallel-group multicentre efficacy and safety phase IIB pilot study of?twice daily versus placebo twice daily

in adult asthmatics during 4 months, AstraZeneca, 2003.

A multicenter, double-blind, randomized, parallel groups placebo-controlled study to assess the efficacy and safety of?BID in subjects with

mild to moderate persistent asthma, Aventis, 2003. 

A double-blind, placebo-controlled, randomized, multicenter study to investigate the safety and efficacy of?over 12 weeks in Diarrhea-

predominant Irritable Bowel Syndrome Subjects, Solvay Pharmaceuticals, Inc., 2003.

A Multi-center, Randomized, Double-Blind, Parallel Group 42-week Comparison of Asthma Control using Bronchial Hyperresponsiveness

as an Additional Guide to a Long-Term Treatment in Adolescents and Adults receiving either?BID or? BID (or placebo BID 

if asymptomatic), GlaxoSmithKline, 2003.

A Randomized, Partly Blinded, Multicenter, Parallel Study Comparing the Efficacy and Safety of ?QD,?QD,?BID,?BID and?BID in Adolescents (12 years of age and older) and Adults with Moderate to Severe Asthma, AstraZeneca, 2003. 

Randomized, double-blind, placebo controlled, parallel design, multicenter study to evaluate the efficacy, tolerability and safety of? 60mg 

CLINICAL TRIALS (Continued)

A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with ? 40mg 

Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates for Once Daily Treatment 

A Placebo-Controlled Comparison of the Efficacy and Safety of the Current US Version of ? and the New Version of ? in Asthmatic

Adults Currently Treated with Inhaled Steroids, AstraZeneca, 2003.

Efficacy and Safety of ? 10mg Versus Placebo in Subjects with Allergic Airway Disease during the Pollen Season, Integrated Therapeutics

Randomized, double-blind, placebo controlled, parallel design, multicenter study to evaluate the efficacy, tolerability and safety of? 60mg 

A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment with ? 40mg 

Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates for Once Daily Treatment 

Adults Currently Treated with Inhaled Steroids, AstraZeneca, 2003.

Efficacy and Safety of ? 10mg Versus Placebo in Subjects with Allergic Airway Disease during the Pollen Season, Integrated Therapeutics

A 12-Week. Double-Blind, Randomized Study of the Safety and Efficacy of Oral? in Subjects with Constipation-Predominant Irritable 

An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of?with Counter in Asthma or COPD Subjects at 

An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of?with Counter in Asthma or COPD Patients at 

An Open-Label, Multicenter Extension Study to Investigate the Long Term Safety of 2mg TID of? in Diarrhea-Predominant Irritable Bowel